Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Osteosarcoma | 83 | 2021 | 929 | 12.190 |
Why?
|
Bone Neoplasms | 64 | 2021 | 2576 | 6.710 |
Why?
|
Sarcoma, Ewing | 32 | 2019 | 406 | 6.270 |
Why?
|
fas Receptor | 22 | 2020 | 185 | 6.090 |
Why?
|
Acetylmuramyl-Alanyl-Isoglutamine | 36 | 2013 | 58 | 3.360 |
Why?
|
Fas Ligand Protein | 11 | 2020 | 150 | 2.980 |
Why?
|
Phosphatidylethanolamines | 30 | 2013 | 63 | 2.880 |
Why?
|
Lung Neoplasms | 54 | 2021 | 11538 | 2.500 |
Why?
|
Pericytes | 9 | 2013 | 96 | 2.400 |
Why?
|
Interleukin-12 | 11 | 2017 | 253 | 2.070 |
Why?
|
Monocytes | 44 | 1999 | 788 | 2.010 |
Why?
|
Neovascularization, Pathologic | 15 | 2013 | 1547 | 1.920 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 2011 | 1533 | 1.820 |
Why?
|
Cardiotoxicity | 4 | 2023 | 155 | 1.770 |
Why?
|
Bone Marrow Cells | 11 | 2013 | 943 | 1.700 |
Why?
|
Mice, Nude | 41 | 2021 | 4307 | 1.690 |
Why?
|
Sarcoma | 7 | 2023 | 1725 | 1.640 |
Why?
|
Doxorubicin | 21 | 2023 | 3005 | 1.400 |
Why?
|
Mice | 88 | 2023 | 34495 | 1.380 |
Why?
|
DNA Topoisomerases, Type II | 11 | 2005 | 116 | 1.310 |
Why?
|
Cytotoxicity, Immunologic | 33 | 1999 | 675 | 1.300 |
Why?
|
Antibiotics, Antineoplastic | 6 | 2023 | 726 | 1.280 |
Why?
|
Interleukin-1 | 23 | 2002 | 461 | 1.270 |
Why?
|
Microtubule-Associated Proteins | 3 | 2018 | 534 | 1.240 |
Why?
|
Anthracyclines | 5 | 2024 | 331 | 1.220 |
Why?
|
Etoposide | 12 | 2008 | 870 | 1.170 |
Why?
|
Exosomes | 2 | 2020 | 253 | 1.170 |
Why?
|
Chemokine CXCL12 | 3 | 2013 | 132 | 1.160 |
Why?
|
Animals | 101 | 2023 | 59536 | 1.160 |
Why?
|
Benzamides | 6 | 2014 | 1832 | 1.040 |
Why?
|
Hodgkin Disease | 2 | 2024 | 1429 | 1.020 |
Why?
|
CASP8 and FADD-Like Apoptosis Regulating Protein | 3 | 2013 | 38 | 1.010 |
Why?
|
Cell Line, Tumor | 41 | 2021 | 14551 | 1.000 |
Why?
|
Genetic Therapy | 8 | 2014 | 1616 | 0.980 |
Why?
|
Exercise Therapy | 3 | 2023 | 288 | 0.970 |
Why?
|
Proto-Oncogene Proteins c-sis | 3 | 2013 | 80 | 0.950 |
Why?
|
Liposomes | 38 | 2001 | 684 | 0.940 |
Why?
|
Tumor Cells, Cultured | 36 | 2020 | 5395 | 0.940 |
Why?
|
Circulating MicroRNA | 1 | 2023 | 25 | 0.940 |
Why?
|
Pyridines | 5 | 2014 | 1244 | 0.920 |
Why?
|
Antineoplastic Agents | 34 | 2014 | 14289 | 0.920 |
Why?
|
Deoxycytidine | 6 | 2014 | 1353 | 0.910 |
Why?
|
Interleukin-2 | 5 | 2020 | 842 | 0.910 |
Why?
|
Mice, Inbred BALB C | 18 | 2021 | 2314 | 0.900 |
Why?
|
Immunologic Factors | 9 | 2013 | 649 | 0.890 |
Why?
|
Killer Cells, Natural | 6 | 2018 | 904 | 0.890 |
Why?
|
Down-Regulation | 10 | 2013 | 2074 | 0.870 |
Why?
|
Cell Movement | 16 | 2016 | 2466 | 0.830 |
Why?
|
Transfection | 17 | 2017 | 2944 | 0.830 |
Why?
|
MicroRNAs | 4 | 2023 | 2947 | 0.800 |
Why?
|
Antineoplastic Agents, Phytogenic | 8 | 2013 | 852 | 0.770 |
Why?
|
Humans | 176 | 2024 | 261506 | 0.740 |
Why?
|
Up-Regulation | 17 | 2021 | 2450 | 0.740 |
Why?
|
Macrophage Activation | 18 | 1995 | 148 | 0.740 |
Why?
|
Adjuvants, Immunologic | 14 | 1999 | 657 | 0.740 |
Why?
|
Tumor Microenvironment | 4 | 2020 | 2864 | 0.730 |
Why?
|
Administration, Inhalation | 4 | 2014 | 285 | 0.730 |
Why?
|
Activities of Daily Living | 1 | 2023 | 552 | 0.720 |
Why?
|
Apoptosis | 16 | 2021 | 7591 | 0.700 |
Why?
|
Signal Transduction | 8 | 2020 | 11965 | 0.690 |
Why?
|
Proto-Oncogene Protein c-fli-1 | 4 | 2014 | 45 | 0.680 |
Why?
|
Gene Expression Regulation, Neoplastic | 16 | 2014 | 8873 | 0.680 |
Why?
|
RNA-Binding Protein EWS | 4 | 2014 | 98 | 0.670 |
Why?
|
Promoter Regions, Genetic | 10 | 2017 | 3101 | 0.670 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2010 | 408 | 0.660 |
Why?
|
Adenovirus E1A Proteins | 3 | 2005 | 163 | 0.650 |
Why?
|
Muscle, Smooth, Vascular | 2 | 2010 | 330 | 0.640 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 2018 | 33 | 0.640 |
Why?
|
Antimetabolites, Antineoplastic | 4 | 2010 | 1299 | 0.600 |
Why?
|
Immunomodulation | 3 | 2018 | 242 | 0.600 |
Why?
|
Neoplasm Metastasis | 15 | 2017 | 5112 | 0.590 |
Why?
|
Cell Communication | 1 | 2020 | 509 | 0.580 |
Why?
|
Ifosfamide | 7 | 2008 | 344 | 0.580 |
Why?
|
Interleukin-11 Receptor alpha Subunit | 2 | 2017 | 14 | 0.570 |
Why?
|
Intercellular Signaling Peptides and Proteins | 7 | 2014 | 650 | 0.570 |
Why?
|
Disease Models, Animal | 13 | 2021 | 7222 | 0.560 |
Why?
|
Cytokines | 12 | 2023 | 2809 | 0.520 |
Why?
|
Xenograft Model Antitumor Assays | 13 | 2019 | 3821 | 0.520 |
Why?
|
Polyethyleneimine | 3 | 2006 | 18 | 0.520 |
Why?
|
RNA, Small Interfering | 7 | 2013 | 2216 | 0.520 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 4 | 2017 | 56 | 0.500 |
Why?
|
Cell Differentiation | 9 | 2014 | 4078 | 0.500 |
Why?
|
Cell Proliferation | 11 | 2018 | 7226 | 0.500 |
Why?
|
Macrophages | 5 | 2018 | 1304 | 0.500 |
Why?
|
Autophagy | 2 | 2018 | 927 | 0.480 |
Why?
|
Tumor Necrosis Factor-alpha | 14 | 1999 | 1538 | 0.470 |
Why?
|
Bone Marrow Transplantation | 4 | 2013 | 1581 | 0.470 |
Why?
|
RNA, Messenger | 20 | 2013 | 6150 | 0.460 |
Why?
|
Camptothecin | 3 | 2013 | 517 | 0.460 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2014 | 755 | 0.450 |
Why?
|
Antigens, Neoplasm | 8 | 2020 | 1506 | 0.450 |
Why?
|
Lymphokines | 12 | 1989 | 272 | 0.440 |
Why?
|
Isoenzymes | 4 | 2005 | 614 | 0.440 |
Why?
|
Phenotype | 5 | 2021 | 6295 | 0.430 |
Why?
|
Immunohistochemistry | 12 | 2018 | 7548 | 0.430 |
Why?
|
Membrane Microdomains | 1 | 2012 | 80 | 0.420 |
Why?
|
Adolescent | 27 | 2024 | 31252 | 0.420 |
Why?
|
Drug Carriers | 17 | 2000 | 327 | 0.420 |
Why?
|
Neoplasm Transplantation | 11 | 2016 | 1519 | 0.410 |
Why?
|
Receptors, CXCR4 | 1 | 2013 | 269 | 0.410 |
Why?
|
Flow Cytometry | 10 | 2014 | 3033 | 0.400 |
Why?
|
Neovascularization, Physiologic | 2 | 2010 | 345 | 0.400 |
Why?
|
Aerosols | 7 | 2010 | 158 | 0.400 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 8 | 2013 | 3639 | 0.390 |
Why?
|
B7-H1 Antigen | 1 | 2018 | 1022 | 0.390 |
Why?
|
Recombinant Proteins | 15 | 2011 | 2927 | 0.390 |
Why?
|
RANK Ligand | 2 | 2009 | 119 | 0.380 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2013 | 612 | 0.380 |
Why?
|
Cell- and Tissue-Based Therapy | 1 | 2013 | 406 | 0.370 |
Why?
|
Mice, Inbred C3H | 5 | 2020 | 385 | 0.350 |
Why?
|
Interferon-gamma | 14 | 2001 | 1144 | 0.350 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 2 | 2008 | 272 | 0.350 |
Why?
|
Alternative Splicing | 2 | 2011 | 584 | 0.340 |
Why?
|
Blotting, Western | 7 | 2013 | 3536 | 0.330 |
Why?
|
Cell Survival | 9 | 2021 | 3045 | 0.330 |
Why?
|
Young Adult | 10 | 2024 | 21445 | 0.330 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.330 |
Why?
|
Osteolysis | 1 | 2009 | 80 | 0.330 |
Why?
|
Antigens, CD34 | 2 | 2008 | 593 | 0.320 |
Why?
|
Cisplatin | 13 | 2008 | 2432 | 0.320 |
Why?
|
Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2007 | 35 | 0.310 |
Why?
|
Topoisomerase II Inhibitors | 2 | 2005 | 58 | 0.310 |
Why?
|
Interleukin-1alpha | 1 | 2008 | 56 | 0.310 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 15862 | 0.310 |
Why?
|
Neoplasms | 16 | 2020 | 15193 | 0.310 |
Why?
|
Muscle, Skeletal | 3 | 2023 | 1270 | 0.300 |
Why?
|
Physical Conditioning, Animal | 2 | 2019 | 112 | 0.300 |
Why?
|
Oxidative Stress | 1 | 2013 | 1129 | 0.300 |
Why?
|
Combined Modality Therapy | 12 | 2018 | 8865 | 0.300 |
Why?
|
Aspergillus fumigatus | 1 | 2007 | 135 | 0.290 |
Why?
|
Endothelium, Vascular | 2 | 2008 | 891 | 0.290 |
Why?
|
Endothelial Cells | 7 | 2019 | 1048 | 0.290 |
Why?
|
Administration, Intranasal | 5 | 2007 | 190 | 0.290 |
Why?
|
Transcription Factors | 5 | 2016 | 5270 | 0.290 |
Why?
|
Lung Diseases, Fungal | 1 | 2007 | 124 | 0.290 |
Why?
|
Lymphocytes | 4 | 2007 | 1234 | 0.290 |
Why?
|
Neoplasm Proteins | 5 | 2019 | 3230 | 0.290 |
Why?
|
CpG Islands | 1 | 2009 | 633 | 0.280 |
Why?
|
Mice, Transgenic | 6 | 2013 | 4143 | 0.280 |
Why?
|
Genetic Vectors | 8 | 2009 | 1694 | 0.280 |
Why?
|
Lung | 6 | 2013 | 3151 | 0.270 |
Why?
|
Cyclooxygenase 2 | 1 | 2008 | 483 | 0.270 |
Why?
|
Repressor Proteins | 1 | 2014 | 1664 | 0.270 |
Why?
|
Receptor, ErbB-2 | 4 | 2009 | 2518 | 0.270 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 3 | 2011 | 153 | 0.270 |
Why?
|
Plasmids | 5 | 2014 | 837 | 0.270 |
Why?
|
Aspergillosis | 1 | 2007 | 246 | 0.270 |
Why?
|
RNA-Binding Proteins | 1 | 2011 | 984 | 0.260 |
Why?
|
src-Family Kinases | 1 | 2008 | 478 | 0.260 |
Why?
|
Membrane Glycoproteins | 3 | 2006 | 1073 | 0.260 |
Why?
|
Cell Line | 15 | 2021 | 5114 | 0.260 |
Why?
|
Heterografts | 3 | 2017 | 733 | 0.260 |
Why?
|
Female | 46 | 2024 | 141928 | 0.260 |
Why?
|
Antibodies | 2 | 2007 | 838 | 0.260 |
Why?
|
Transcription, Genetic | 8 | 2013 | 3154 | 0.260 |
Why?
|
Immunoenzyme Techniques | 3 | 2013 | 1165 | 0.250 |
Why?
|
Calcium-Binding Proteins | 3 | 2014 | 545 | 0.250 |
Why?
|
Soft Tissue Neoplasms | 2 | 2022 | 882 | 0.250 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.250 |
Why?
|
HEK293 Cells | 4 | 2020 | 1489 | 0.250 |
Why?
|
Stem Cells | 2 | 2014 | 1213 | 0.250 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2007 | 749 | 0.240 |
Why?
|
Child | 22 | 2018 | 29154 | 0.240 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2006 | 588 | 0.240 |
Why?
|
Biomarkers, Tumor | 6 | 2018 | 10331 | 0.240 |
Why?
|
Integrin alphaVbeta3 | 1 | 2004 | 45 | 0.240 |
Why?
|
Male | 38 | 2019 | 123000 | 0.230 |
Why?
|
Bone Density Conservation Agents | 1 | 2005 | 198 | 0.230 |
Why?
|
Diphosphonates | 1 | 2005 | 262 | 0.230 |
Why?
|
Phosphatidylglycerols | 2 | 2001 | 33 | 0.230 |
Why?
|
Troponin | 1 | 2023 | 92 | 0.230 |
Why?
|
Cells, Cultured | 19 | 2009 | 5637 | 0.230 |
Why?
|
DNA-Binding Proteins | 7 | 2005 | 4821 | 0.230 |
Why?
|
Recovery of Function | 1 | 2007 | 703 | 0.230 |
Why?
|
Monocytes, Activated Killer | 2 | 1993 | 2 | 0.220 |
Why?
|
Immunocompromised Host | 1 | 2007 | 698 | 0.220 |
Why?
|
Neurons | 1 | 2014 | 2287 | 0.220 |
Why?
|
Macrophage-Activating Factors | 12 | 1999 | 12 | 0.220 |
Why?
|
Adaptor Proteins, Signal Transducing | 4 | 2021 | 1439 | 0.220 |
Why?
|
Phosphatidylcholines | 2 | 2001 | 144 | 0.220 |
Why?
|
T-Lymphocytes | 3 | 2020 | 3869 | 0.220 |
Why?
|
Cigarette Smoking | 1 | 2023 | 88 | 0.220 |
Why?
|
Nuclear Proteins | 2 | 2011 | 3343 | 0.220 |
Why?
|
Peptides | 5 | 2017 | 1479 | 0.220 |
Why?
|
Adenoviridae | 6 | 2008 | 1459 | 0.210 |
Why?
|
Methotrexate | 6 | 2008 | 999 | 0.210 |
Why?
|
Hematopoietic Stem Cells | 1 | 2008 | 1242 | 0.210 |
Why?
|
Neoplasms, Experimental | 6 | 2018 | 750 | 0.210 |
Why?
|
Cyclophosphamide | 3 | 2007 | 3001 | 0.200 |
Why?
|
Herpes Simplex | 3 | 1990 | 95 | 0.200 |
Why?
|
Technetium Tc 99m Dimercaptosuccinic Acid | 1 | 2021 | 1 | 0.200 |
Why?
|
Organic Anion Transporters, Sodium-Independent | 1 | 2021 | 2 | 0.200 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 2 | 2016 | 622 | 0.200 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2005 | 5178 | 0.200 |
Why?
|
Paclitaxel | 2 | 2005 | 1996 | 0.200 |
Why?
|
Gene Transfer Techniques | 4 | 2009 | 716 | 0.200 |
Why?
|
Antibodies, Monoclonal | 9 | 2014 | 4367 | 0.200 |
Why?
|
Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 84 | 0.190 |
Why?
|
Melanoma, Experimental | 2 | 2020 | 368 | 0.190 |
Why?
|
3-Iodobenzylguanidine | 1 | 2020 | 31 | 0.190 |
Why?
|
Adult | 25 | 2023 | 77950 | 0.190 |
Why?
|
Survival Analysis | 5 | 2020 | 9180 | 0.190 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2020 | 83 | 0.190 |
Why?
|
Integrin alpha Chains | 1 | 2020 | 28 | 0.190 |
Why?
|
Prognosis | 8 | 2023 | 21713 | 0.190 |
Why?
|
DNA Primers | 3 | 2011 | 1399 | 0.180 |
Why?
|
Genes, erbB-2 | 1 | 2001 | 229 | 0.180 |
Why?
|
Macrophages, Alveolar | 1 | 2020 | 67 | 0.180 |
Why?
|
Sarcoma, Experimental | 1 | 2020 | 68 | 0.180 |
Why?
|
Child, Preschool | 10 | 2018 | 16273 | 0.180 |
Why?
|
Drug Synergism | 6 | 2006 | 1313 | 0.180 |
Why?
|
Sp7 Transcription Factor | 3 | 2016 | 27 | 0.180 |
Why?
|
Feasibility Studies | 4 | 2017 | 2292 | 0.180 |
Why?
|
Sarcopenia | 1 | 2021 | 110 | 0.180 |
Why?
|
Membrane Proteins | 1 | 2010 | 2819 | 0.180 |
Why?
|
Imidazoles | 1 | 2005 | 999 | 0.180 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2021 | 324 | 0.180 |
Why?
|
Health Status | 1 | 2023 | 590 | 0.180 |
Why?
|
Heart Function Tests | 1 | 2019 | 73 | 0.170 |
Why?
|
Leukocytes, Mononuclear | 4 | 1995 | 709 | 0.170 |
Why?
|
Alpha Particles | 1 | 2019 | 26 | 0.170 |
Why?
|
Capillary Permeability | 1 | 2019 | 114 | 0.170 |
Why?
|
Stroke Volume | 1 | 2021 | 577 | 0.170 |
Why?
|
In Vitro Techniques | 9 | 2020 | 1618 | 0.170 |
Why?
|
DNA Methylation | 1 | 2009 | 2669 | 0.160 |
Why?
|
Proteoglycans | 2 | 2011 | 259 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2016 | 3890 | 0.160 |
Why?
|
Dendritic Cells | 2 | 2020 | 1085 | 0.160 |
Why?
|
Chemokine CCL2 | 2 | 1996 | 203 | 0.160 |
Why?
|
Neuroblastoma | 2 | 2020 | 686 | 0.160 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2017 | 1586 | 0.160 |
Why?
|
Radium | 1 | 2019 | 93 | 0.150 |
Why?
|
Diet Therapy | 1 | 2017 | 52 | 0.150 |
Why?
|
RNA, Long Noncoding | 2 | 2014 | 598 | 0.150 |
Why?
|
Osteoprotegerin | 2 | 2008 | 24 | 0.150 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 615 | 0.150 |
Why?
|
Gene Expression Regulation | 3 | 1999 | 4053 | 0.150 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 2014 | 494 | 0.140 |
Why?
|
RNA Interference | 3 | 2012 | 1408 | 0.140 |
Why?
|
Melanoma | 15 | 1999 | 5317 | 0.140 |
Why?
|
Osteoclasts | 2 | 2009 | 165 | 0.140 |
Why?
|
DNA Topoisomerases, Type I | 1 | 1996 | 57 | 0.140 |
Why?
|
Interleukin-27 | 1 | 2016 | 8 | 0.140 |
Why?
|
Cell Growth Processes | 2 | 2008 | 342 | 0.140 |
Why?
|
Mice, Inbred C57BL | 7 | 2020 | 6942 | 0.140 |
Why?
|
GPI-Linked Proteins | 2 | 2013 | 223 | 0.140 |
Why?
|
Blotting, Northern | 4 | 2002 | 682 | 0.140 |
Why?
|
Tissue Array Analysis | 1 | 2018 | 760 | 0.140 |
Why?
|
Survival Rate | 7 | 2013 | 12221 | 0.140 |
Why?
|
Neoplasm Grading | 2 | 2018 | 1742 | 0.130 |
Why?
|
Chemotaxis | 2 | 2007 | 138 | 0.130 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2006 | 157 | 0.130 |
Why?
|
Blood Pressure | 1 | 2021 | 1467 | 0.130 |
Why?
|
Exercise | 1 | 2023 | 1183 | 0.130 |
Why?
|
Lipopolysaccharides | 8 | 1991 | 558 | 0.130 |
Why?
|
Nursing Research | 1 | 1995 | 18 | 0.130 |
Why?
|
Disease-Free Survival | 7 | 2010 | 10001 | 0.130 |
Why?
|
Histone Acetyltransferases | 1 | 2017 | 411 | 0.130 |
Why?
|
Antigens, CD | 1 | 2020 | 1385 | 0.130 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2005 | 703 | 0.130 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2016 | 3552 | 0.130 |
Why?
|
Osteogenesis | 1 | 2016 | 271 | 0.130 |
Why?
|
Physicians, Family | 1 | 1995 | 54 | 0.130 |
Why?
|
Vaccines | 1 | 2020 | 389 | 0.130 |
Why?
|
Cell Separation | 7 | 2004 | 612 | 0.120 |
Why?
|
Base Sequence | 3 | 2014 | 4917 | 0.120 |
Why?
|
Cell Division | 7 | 2001 | 2489 | 0.120 |
Why?
|
Fluorescent Antibody Technique | 2 | 2014 | 1062 | 0.120 |
Why?
|
Chemotactic Factors | 1 | 1994 | 42 | 0.120 |
Why?
|
Microscopy, Fluorescence | 2 | 2014 | 769 | 0.120 |
Why?
|
Transcription Factor HES-1 | 1 | 2014 | 49 | 0.120 |
Why?
|
Neoplasm Invasiveness | 3 | 2013 | 3981 | 0.120 |
Why?
|
Cell Adhesion | 3 | 2004 | 1008 | 0.120 |
Why?
|
Biomarkers | 2 | 2023 | 5047 | 0.120 |
Why?
|
HeLa Cells | 1 | 2017 | 1643 | 0.120 |
Why?
|
Autophagy-Related Protein 5 | 1 | 2013 | 46 | 0.120 |
Why?
|
Buthionine Sulfoximine | 1 | 2013 | 41 | 0.120 |
Why?
|
Drug Interactions | 4 | 2005 | 553 | 0.120 |
Why?
|
Benzylamines | 1 | 2013 | 105 | 0.120 |
Why?
|
Polymorphism, Genetic | 2 | 2010 | 1450 | 0.120 |
Why?
|
Caspases | 2 | 2013 | 661 | 0.120 |
Why?
|
Tissue Distribution | 4 | 2021 | 875 | 0.120 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2013 | 4938 | 0.110 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2013 | 133 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 1489 | 0.110 |
Why?
|
Gene Expression | 2 | 2018 | 3570 | 0.110 |
Why?
|
Heterocyclic Compounds | 1 | 2013 | 119 | 0.110 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 1011 | 0.110 |
Why?
|
Actins | 2 | 2013 | 608 | 0.110 |
Why?
|
Gene Knockdown Techniques | 2 | 2013 | 1077 | 0.110 |
Why?
|
Cell Hypoxia | 1 | 2014 | 328 | 0.110 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 2 | 2009 | 591 | 0.110 |
Why?
|
Vimentin | 1 | 2014 | 253 | 0.110 |
Why?
|
Ibuprofen | 1 | 1993 | 56 | 0.110 |
Why?
|
Actin Cytoskeleton | 1 | 2013 | 82 | 0.110 |
Why?
|
Pharmaceutical Vehicles | 2 | 2009 | 15 | 0.110 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2013 | 110 | 0.110 |
Why?
|
Treatment Outcome | 9 | 2020 | 32848 | 0.110 |
Why?
|
Salvage Therapy | 4 | 2008 | 2054 | 0.110 |
Why?
|
Retroviridae Proteins | 2 | 1989 | 20 | 0.110 |
Why?
|
Cell Cycle | 4 | 2002 | 2084 | 0.110 |
Why?
|
Pediatric Obesity | 1 | 2017 | 364 | 0.110 |
Why?
|
Drug Resistance, Multiple | 3 | 1999 | 204 | 0.110 |
Why?
|
Transplantation, Heterologous | 3 | 2016 | 1082 | 0.110 |
Why?
|
Time Factors | 9 | 2013 | 12926 | 0.110 |
Why?
|
Gene Silencing | 2 | 2013 | 837 | 0.110 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2014 | 503 | 0.110 |
Why?
|
Neoplasm Staging | 4 | 2019 | 13658 | 0.110 |
Why?
|
Myocardial Infarction | 1 | 2021 | 1374 | 0.100 |
Why?
|
Immunosuppressive Agents | 2 | 2007 | 1375 | 0.100 |
Why?
|
ets-Domain Protein Elk-1 | 1 | 2011 | 19 | 0.100 |
Why?
|
Colony-Stimulating Factors | 2 | 1990 | 82 | 0.100 |
Why?
|
Interleukins | 3 | 2001 | 325 | 0.100 |
Why?
|
Clinical Trials as Topic | 4 | 1995 | 3719 | 0.100 |
Why?
|
Injections, Intravenous | 3 | 2009 | 573 | 0.100 |
Why?
|
Gene Products, gag | 2 | 1990 | 36 | 0.100 |
Why?
|
Cell Adhesion Molecules | 1 | 1995 | 577 | 0.100 |
Why?
|
Desmin | 1 | 2011 | 63 | 0.100 |
Why?
|
Species Specificity | 2 | 2010 | 777 | 0.100 |
Why?
|
Tumor Burden | 3 | 2020 | 1987 | 0.100 |
Why?
|
Heart | 1 | 2018 | 1223 | 0.100 |
Why?
|
Immunotherapy | 7 | 2020 | 3341 | 0.100 |
Why?
|
H-2 Antigens | 1 | 2010 | 42 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2017 | 566 | 0.100 |
Why?
|
Electroporation | 1 | 2011 | 126 | 0.100 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2013 | 10035 | 0.100 |
Why?
|
Antigens | 1 | 2011 | 292 | 0.090 |
Why?
|
Leukocyte Count | 4 | 2007 | 684 | 0.090 |
Why?
|
Protein Transport | 1 | 2013 | 734 | 0.090 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2014 | 992 | 0.090 |
Why?
|
MAP Kinase Kinase Kinase 3 | 1 | 2010 | 21 | 0.090 |
Why?
|
Dogs | 4 | 2014 | 1155 | 0.090 |
Why?
|
Receptors, CXCR3 | 1 | 2009 | 36 | 0.090 |
Why?
|
Breast Neoplasms | 6 | 2005 | 15694 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2013 | 1764 | 0.090 |
Why?
|
Lithium | 1 | 1989 | 71 | 0.090 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 205 | 0.090 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2011 | 518 | 0.090 |
Why?
|
Interleukin-4 | 1 | 1990 | 284 | 0.090 |
Why?
|
Chlorides | 1 | 1989 | 139 | 0.090 |
Why?
|
Interleukin-1beta | 1 | 2010 | 300 | 0.090 |
Why?
|
Simplexvirus | 1 | 1990 | 159 | 0.090 |
Why?
|
Biological Transport | 2 | 2021 | 597 | 0.090 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.090 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 502 | 0.090 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 1995 | 1493 | 0.090 |
Why?
|
Middle Aged | 14 | 2019 | 86204 | 0.080 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2014 | 607 | 0.080 |
Why?
|
Amsacrine | 3 | 1996 | 61 | 0.080 |
Why?
|
Deltaretrovirus | 2 | 1987 | 7 | 0.080 |
Why?
|
Cytotoxicity Tests, Immunologic | 4 | 1993 | 84 | 0.080 |
Why?
|
Dinoprostone | 1 | 1990 | 208 | 0.080 |
Why?
|
Colonic Neoplasms | 2 | 2013 | 1390 | 0.080 |
Why?
|
Ataxins | 1 | 2008 | 91 | 0.080 |
Why?
|
Extracellular Fluid | 1 | 2008 | 19 | 0.080 |
Why?
|
Receptor, Notch1 | 1 | 2010 | 218 | 0.080 |
Why?
|
Protein Isoforms | 2 | 2008 | 842 | 0.080 |
Why?
|
DNA Modification Methylases | 1 | 2009 | 172 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 2 | 2024 | 7551 | 0.080 |
Why?
|
Kinetics | 5 | 1996 | 2049 | 0.080 |
Why?
|
Homeodomain Proteins | 1 | 2014 | 1143 | 0.080 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 663 | 0.080 |
Why?
|
Receptors, Chemokine | 1 | 2008 | 114 | 0.080 |
Why?
|
Binding Sites | 2 | 2013 | 2171 | 0.080 |
Why?
|
Transduction, Genetic | 3 | 2009 | 475 | 0.080 |
Why?
|
Fas-Associated Death Domain Protein | 1 | 2007 | 25 | 0.080 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2008 | 157 | 0.080 |
Why?
|
Retroviridae Proteins, Oncogenic | 1 | 1987 | 36 | 0.080 |
Why?
|
Thrombospondins | 1 | 2007 | 21 | 0.080 |
Why?
|
Ataxin-1 | 1 | 2008 | 148 | 0.080 |
Why?
|
Bone Resorption | 1 | 2008 | 138 | 0.080 |
Why?
|
Introns | 1 | 2009 | 432 | 0.080 |
Why?
|
Growth Substances | 1 | 1988 | 300 | 0.080 |
Why?
|
Sp1 Transcription Factor | 1 | 2008 | 188 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2016 | 2359 | 0.070 |
Why?
|
DNA, Antisense | 1 | 2006 | 42 | 0.070 |
Why?
|
Peptide Fragments | 2 | 1990 | 1271 | 0.070 |
Why?
|
Embryo, Mammalian | 1 | 2010 | 741 | 0.070 |
Why?
|
Infusions, Intravenous | 4 | 1993 | 1382 | 0.070 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 1399 | 0.070 |
Why?
|
Tumor Necrosis Factors | 1 | 2006 | 34 | 0.070 |
Why?
|
RNA | 2 | 2007 | 1013 | 0.070 |
Why?
|
Mice, Mutant Strains | 1 | 2007 | 634 | 0.070 |
Why?
|
Viral Envelope Proteins | 1 | 1987 | 207 | 0.070 |
Why?
|
Laminin | 1 | 2006 | 194 | 0.070 |
Why?
|
Injections, Intralesional | 1 | 2006 | 164 | 0.070 |
Why?
|
Oligopeptides | 2 | 2004 | 429 | 0.070 |
Why?
|
Luciferases, Firefly | 1 | 2005 | 39 | 0.070 |
Why?
|
Mutation | 3 | 2023 | 15179 | 0.070 |
Why?
|
Tumor Stem Cell Assay | 2 | 1996 | 231 | 0.070 |
Why?
|
Microfilament Proteins | 1 | 2009 | 487 | 0.070 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2001 | 665 | 0.070 |
Why?
|
Platelet Count | 1 | 2007 | 490 | 0.070 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2001 | 604 | 0.070 |
Why?
|
Quality of Life | 1 | 2020 | 4532 | 0.070 |
Why?
|
Brain Neoplasms | 6 | 2014 | 4849 | 0.070 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2006 | 223 | 0.070 |
Why?
|
Proliferating Cell Nuclear Antigen | 1 | 2006 | 195 | 0.070 |
Why?
|
Oncolytic Viruses | 1 | 2008 | 204 | 0.070 |
Why?
|
Aged | 8 | 2019 | 70117 | 0.070 |
Why?
|
Glioblastoma | 1 | 1996 | 1797 | 0.070 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2005 | 184 | 0.060 |
Why?
|
Receptor Activator of Nuclear Factor-kappa B | 1 | 2005 | 46 | 0.060 |
Why?
|
Paraffin Embedding | 1 | 2005 | 226 | 0.060 |
Why?
|
Cadherins | 1 | 2008 | 660 | 0.060 |
Why?
|
Thymidine | 1 | 2004 | 155 | 0.060 |
Why?
|
Oncolytic Virotherapy | 1 | 2008 | 280 | 0.060 |
Why?
|
Skin Neoplasms | 2 | 1998 | 4654 | 0.060 |
Why?
|
Drug Combinations | 1 | 2006 | 621 | 0.060 |
Why?
|
Spinal Cord Compression | 1 | 1986 | 151 | 0.060 |
Why?
|
Piperazines | 2 | 2010 | 2101 | 0.060 |
Why?
|
Vitronectin | 1 | 2004 | 22 | 0.060 |
Why?
|
Neutrophils | 1 | 1989 | 835 | 0.060 |
Why?
|
Receptors, Vitronectin | 1 | 2004 | 24 | 0.060 |
Why?
|
Disease Progression | 3 | 2014 | 6682 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 6915 | 0.060 |
Why?
|
Injections, Intraperitoneal | 2 | 2002 | 197 | 0.060 |
Why?
|
beta-Galactosidase | 1 | 2003 | 211 | 0.060 |
Why?
|
Integrin alpha4 | 1 | 2003 | 25 | 0.060 |
Why?
|
Sarcoma, Kaposi | 1 | 1985 | 187 | 0.060 |
Why?
|
Genes, Reporter | 1 | 2005 | 798 | 0.060 |
Why?
|
Bone Marrow Diseases | 2 | 1997 | 177 | 0.060 |
Why?
|
Inhibitory Concentration 50 | 1 | 2004 | 289 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 2330 | 0.060 |
Why?
|
In Situ Nick-End Labeling | 1 | 2003 | 448 | 0.060 |
Why?
|
Collagen | 1 | 2006 | 752 | 0.060 |
Why?
|
Anoikis | 1 | 2003 | 63 | 0.060 |
Why?
|
Immunity, Innate | 2 | 1990 | 677 | 0.060 |
Why?
|
Pneumonectomy | 1 | 2008 | 831 | 0.060 |
Why?
|
Fibrosis | 2 | 1997 | 793 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1985 | 362 | 0.060 |
Why?
|
Radioisotopes | 2 | 2019 | 177 | 0.050 |
Why?
|
Connective Tissue | 1 | 2022 | 43 | 0.050 |
Why?
|
Azacitidine | 1 | 2009 | 1149 | 0.050 |
Why?
|
Trastuzumab | 1 | 2005 | 696 | 0.050 |
Why?
|
Fever | 2 | 1997 | 497 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2022 | 37905 | 0.050 |
Why?
|
Trans-Activators | 1 | 2009 | 1555 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2013 | 14889 | 0.050 |
Why?
|
Rats | 3 | 2007 | 6086 | 0.050 |
Why?
|
Aged, 80 and over | 3 | 2018 | 29902 | 0.050 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1986 | 393 | 0.050 |
Why?
|
Observational Studies as Topic | 1 | 2022 | 140 | 0.050 |
Why?
|
Glycoproteins | 1 | 2005 | 747 | 0.050 |
Why?
|
Ribose | 1 | 2021 | 32 | 0.050 |
Why?
|
Kupffer Cells | 2 | 1993 | 42 | 0.050 |
Why?
|
Hematopoietic Cell Growth Factors | 1 | 2001 | 38 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2005 | 2315 | 0.050 |
Why?
|
Interleukin-8 | 2 | 1994 | 519 | 0.050 |
Why?
|
Adenosine Diphosphate | 1 | 2021 | 113 | 0.050 |
Why?
|
Sex Factors | 1 | 2007 | 2139 | 0.050 |
Why?
|
Salicylates | 1 | 1981 | 59 | 0.050 |
Why?
|
Dexamethasone | 2 | 1996 | 1450 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2009 | 1879 | 0.050 |
Why?
|
Isotretinoin | 1 | 2001 | 158 | 0.050 |
Why?
|
Radiography | 1 | 2005 | 1904 | 0.050 |
Why?
|
Drug Evaluation | 2 | 1992 | 425 | 0.050 |
Why?
|
Oxygen | 1 | 1985 | 754 | 0.050 |
Why?
|
Feedback | 1 | 2021 | 198 | 0.050 |
Why?
|
Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 170 | 0.050 |
Why?
|
Heart Neoplasms | 1 | 2003 | 214 | 0.050 |
Why?
|
Phagocytosis | 4 | 1988 | 260 | 0.050 |
Why?
|
Cell Membrane | 3 | 1990 | 850 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2008 | 1491 | 0.050 |
Why?
|
Immunoblotting | 2 | 1993 | 886 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2010 | 6009 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 6207 | 0.050 |
Why?
|
Cross-Priming | 1 | 2020 | 39 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 1981 | 673 | 0.050 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2004 | 444 | 0.050 |
Why?
|
Neutropenia | 2 | 1997 | 968 | 0.050 |
Why?
|
Infant | 5 | 2009 | 13310 | 0.040 |
Why?
|
Hydrocortisone | 1 | 1981 | 388 | 0.040 |
Why?
|
Preoperative Care | 1 | 2005 | 1529 | 0.040 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2014 | 3251 | 0.040 |
Why?
|
Antigen Presentation | 1 | 2020 | 272 | 0.040 |
Why?
|
Cytosol | 2 | 1990 | 238 | 0.040 |
Why?
|
Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 37 | 0.040 |
Why?
|
Drug Design | 1 | 2001 | 375 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 2 | 2014 | 4757 | 0.040 |
Why?
|
NF-kappa B | 1 | 2005 | 1549 | 0.040 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2023 | 801 | 0.040 |
Why?
|
Consensus | 1 | 2022 | 978 | 0.040 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2021 | 621 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2009 | 3472 | 0.040 |
Why?
|
Protein Kinase C | 2 | 1990 | 396 | 0.040 |
Why?
|
Capillary Leak Syndrome | 1 | 1997 | 14 | 0.040 |
Why?
|
Mitochondria | 2 | 2021 | 1282 | 0.040 |
Why?
|
Vinblastine | 1 | 1999 | 453 | 0.040 |
Why?
|
Pyrimidines | 1 | 2010 | 3518 | 0.040 |
Why?
|
Retroviridae | 2 | 2009 | 332 | 0.040 |
Why?
|
Respiration Disorders | 1 | 1997 | 45 | 0.040 |
Why?
|
Reactive Oxygen Species | 1 | 2022 | 987 | 0.040 |
Why?
|
Femoral Neoplasms | 1 | 1997 | 64 | 0.040 |
Why?
|
Nucleocytoplasmic Transport Proteins | 1 | 2017 | 22 | 0.040 |
Why?
|
Autocrine Communication | 1 | 2017 | 84 | 0.040 |
Why?
|
Tetradecanoylphorbol Acetate | 2 | 1989 | 226 | 0.040 |
Why?
|
Nuclear Matrix-Associated Proteins | 1 | 2017 | 33 | 0.040 |
Why?
|
Age Factors | 1 | 2007 | 5377 | 0.040 |
Why?
|
Core Binding Factor Alpha 1 Subunit | 1 | 2016 | 30 | 0.040 |
Why?
|
Alopecia | 1 | 1997 | 126 | 0.040 |
Why?
|
Hot Temperature | 2 | 1990 | 281 | 0.040 |
Why?
|
Restriction Mapping | 1 | 1996 | 264 | 0.040 |
Why?
|
Mice, Knockout | 2 | 2017 | 5710 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2005 | 2022 | 0.040 |
Why?
|
Mammary Tumor Virus, Mouse | 1 | 1996 | 122 | 0.030 |
Why?
|
Polymyxin B | 3 | 1985 | 53 | 0.030 |
Why?
|
Receptors, Interleukin | 1 | 2016 | 97 | 0.030 |
Why?
|
Hypotension | 1 | 1997 | 210 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2007 | 4549 | 0.030 |
Why?
|
Gangliosides | 1 | 1996 | 95 | 0.030 |
Why?
|
X-Ray Microtomography | 1 | 2016 | 141 | 0.030 |
Why?
|
Job Description | 1 | 1995 | 16 | 0.030 |
Why?
|
Neoadjuvant Therapy | 1 | 2008 | 4975 | 0.030 |
Why?
|
Immunity, Cellular | 2 | 1989 | 419 | 0.030 |
Why?
|
Interferon-alpha | 1 | 1999 | 889 | 0.030 |
Why?
|
Lymphocyte Function-Associated Antigen-1 | 1 | 1995 | 72 | 0.030 |
Why?
|
Phosphorylation | 2 | 2021 | 4804 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 1998 | 1363 | 0.030 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 1995 | 221 | 0.030 |
Why?
|
Genotype | 2 | 2016 | 4109 | 0.030 |
Why?
|
Liver | 1 | 2004 | 2961 | 0.030 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2014 | 189 | 0.030 |
Why?
|
Proteomics | 1 | 2021 | 1380 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 1995 | 543 | 0.030 |
Why?
|
Half-Life | 1 | 1994 | 259 | 0.030 |
Why?
|
Chemotaxis, Leukocyte | 1 | 1994 | 157 | 0.030 |
Why?
|
Human Umbilical Vein Endothelial Cells | 1 | 2014 | 164 | 0.030 |
Why?
|
Cell Death | 1 | 1996 | 671 | 0.030 |
Why?
|
Integrins | 1 | 1995 | 262 | 0.030 |
Why?
|
Weight Loss | 1 | 2017 | 627 | 0.030 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 1994 | 154 | 0.030 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2019 | 833 | 0.030 |
Why?
|
Serum Albumin, Bovine | 2 | 1990 | 83 | 0.030 |
Why?
|
Neopterin | 1 | 1992 | 13 | 0.030 |
Why?
|
Gastrointestinal Diseases | 1 | 1997 | 589 | 0.030 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2013 | 235 | 0.030 |
Why?
|
Acetylation | 1 | 2013 | 508 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 2 | 2014 | 1248 | 0.030 |
Why?
|
Coculture Techniques | 1 | 2013 | 626 | 0.030 |
Why?
|
Carcinoma | 2 | 1999 | 2578 | 0.030 |
Why?
|
Safety | 1 | 2013 | 465 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2013 | 905 | 0.020 |
Why?
|
Prospective Studies | 2 | 2022 | 12873 | 0.020 |
Why?
|
Remission Induction | 1 | 1997 | 3569 | 0.020 |
Why?
|
Splenic Neoplasms | 1 | 1992 | 119 | 0.020 |
Why?
|
Nucleocapsid Proteins | 1 | 1990 | 12 | 0.020 |
Why?
|
Ligands | 1 | 2013 | 995 | 0.020 |
Why?
|
Gene Amplification | 1 | 2014 | 731 | 0.020 |
Why?
|
Drosophila | 1 | 1996 | 839 | 0.020 |
Why?
|
Agammaglobulinemia | 1 | 1990 | 46 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1996 | 1555 | 0.020 |
Why?
|
Phytohemagglutinins | 1 | 1990 | 71 | 0.020 |
Why?
|
Vaccinia | 1 | 1990 | 11 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2014 | 470 | 0.020 |
Why?
|
Bevacizumab | 1 | 2014 | 938 | 0.020 |
Why?
|
Lithium Chloride | 1 | 1989 | 28 | 0.020 |
Why?
|
Biotechnology | 1 | 1990 | 63 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 1995 | 1910 | 0.020 |
Why?
|
RNA, Antisense | 1 | 2009 | 69 | 0.020 |
Why?
|
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1989 | 14 | 0.020 |
Why?
|
Risk Factors | 1 | 2007 | 17523 | 0.020 |
Why?
|
Sirolimus | 1 | 2014 | 814 | 0.020 |
Why?
|
Kidney Neoplasms | 2 | 1995 | 3022 | 0.020 |
Why?
|
Leukocytosis | 1 | 1989 | 112 | 0.020 |
Why?
|
Carcinoma, Renal Cell | 2 | 2008 | 2326 | 0.020 |
Why?
|
Molecular Weight | 1 | 1990 | 629 | 0.020 |
Why?
|
Neoplasm, Residual | 1 | 1995 | 1656 | 0.020 |
Why?
|
Receptors, Interleukin-1 | 1 | 1989 | 93 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 1990 | 568 | 0.020 |
Why?
|
Interleukin-6 | 1 | 1994 | 1038 | 0.020 |
Why?
|
Binding, Competitive | 1 | 1989 | 300 | 0.020 |
Why?
|
Hybrid Cells | 1 | 1989 | 128 | 0.020 |
Why?
|
Isoquinolines | 1 | 1989 | 116 | 0.020 |
Why?
|
Acetamides | 1 | 2009 | 113 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 1992 | 527 | 0.020 |
Why?
|
Medical Oncology | 1 | 2017 | 1423 | 0.020 |
Why?
|
CD28 Antigens | 1 | 2009 | 202 | 0.020 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 1990 | 238 | 0.020 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 598 | 0.020 |
Why?
|
Pediatrics | 1 | 2017 | 1141 | 0.020 |
Why?
|
Leukemia, Lymphoid | 1 | 1989 | 276 | 0.020 |
Why?
|
DNA | 1 | 1996 | 2693 | 0.020 |
Why?
|
Depression, Chemical | 1 | 1987 | 52 | 0.020 |
Why?
|
Endotoxins | 2 | 1985 | 96 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 2283 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2009 | 314 | 0.020 |
Why?
|
Ultraviolet Rays | 1 | 1990 | 575 | 0.020 |
Why?
|
Lymphocyte Activation | 2 | 1993 | 1688 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 1989 | 309 | 0.020 |
Why?
|
DNA, Viral | 1 | 1990 | 694 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 1987 | 354 | 0.020 |
Why?
|
Temperature | 1 | 1989 | 506 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2007 | 260 | 0.020 |
Why?
|
Capsid Proteins | 1 | 2008 | 185 | 0.020 |
Why?
|
Virus Replication | 1 | 1990 | 709 | 0.020 |
Why?
|
Myelography | 1 | 1986 | 16 | 0.020 |
Why?
|
Histones | 1 | 2013 | 1466 | 0.020 |
Why?
|
HIV | 1 | 1987 | 229 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 1986 | 255 | 0.020 |
Why?
|
Paresthesia | 1 | 1986 | 33 | 0.020 |
Why?
|
Imatinib Mesylate | 1 | 2010 | 1665 | 0.020 |
Why?
|
Epidural Space | 1 | 1986 | 42 | 0.020 |
Why?
|
Prostaglandins E | 2 | 1985 | 23 | 0.020 |
Why?
|
Salmonella typhi | 1 | 1985 | 15 | 0.020 |
Why?
|
Thymoma | 1 | 1989 | 246 | 0.020 |
Why?
|
Reference Values | 1 | 2007 | 1099 | 0.020 |
Why?
|
Indomethacin | 2 | 1985 | 91 | 0.020 |
Why?
|
Catalase | 1 | 1985 | 70 | 0.020 |
Why?
|
Indium | 1 | 1985 | 20 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 4971 | 0.020 |
Why?
|
Mice, SCID | 1 | 2009 | 1869 | 0.020 |
Why?
|
Superoxides | 1 | 1985 | 211 | 0.020 |
Why?
|
Kidney | 2 | 1984 | 2146 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 1980 | 4638 | 0.020 |
Why?
|
Hydrogen Peroxide | 1 | 1985 | 217 | 0.020 |
Why?
|
Gastrointestinal Neoplasms | 1 | 1989 | 600 | 0.020 |
Why?
|
Superoxide Dismutase | 1 | 1985 | 266 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2005 | 521 | 0.010 |
Why?
|
Exons | 1 | 2007 | 1328 | 0.010 |
Why?
|
Granuloma | 1 | 1985 | 154 | 0.010 |
Why?
|
Complement System Proteins | 1 | 1984 | 139 | 0.010 |
Why?
|
Cytochromes c | 1 | 2003 | 118 | 0.010 |
Why?
|
Calcium | 1 | 2009 | 1537 | 0.010 |
Why?
|
Models, Genetic | 1 | 2007 | 1113 | 0.010 |
Why?
|
Adenocarcinoma | 2 | 1993 | 7789 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2009 | 1146 | 0.010 |
Why?
|
Aminoacridines | 1 | 1982 | 23 | 0.010 |
Why?
|
Prostate | 1 | 2008 | 1088 | 0.010 |
Why?
|
Endocytosis | 1 | 1983 | 225 | 0.010 |
Why?
|
Dactinomycin | 1 | 1982 | 145 | 0.010 |
Why?
|
Proteins | 1 | 1990 | 1963 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 1986 | 509 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 2508 | 0.010 |
Why?
|
Stimulation, Chemical | 1 | 1980 | 97 | 0.010 |
Why?
|
X-Rays | 1 | 1980 | 146 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1981 | 726 | 0.010 |
Why?
|
Particle Size | 1 | 2000 | 182 | 0.010 |
Why?
|
Microscopy, Electron | 1 | 2000 | 600 | 0.010 |
Why?
|
Melphalan | 1 | 1982 | 834 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 1996 | 5061 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 1981 | 461 | 0.010 |
Why?
|
Aspirin | 1 | 1981 | 455 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 7702 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2009 | 8223 | 0.010 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 1996 | 84 | 0.010 |
Why?
|
Immunotherapy, Active | 1 | 1996 | 46 | 0.010 |
Why?
|
Leukemia | 1 | 2005 | 1635 | 0.010 |
Why?
|
Immunization, Passive | 1 | 1996 | 172 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2007 | 5539 | 0.010 |
Why?
|
Fatal Outcome | 1 | 1996 | 829 | 0.010 |
Why?
|
Immune Sera | 1 | 1993 | 146 | 0.010 |
Why?
|
Glioma | 1 | 1983 | 1963 | 0.010 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 1990 | 15 | 0.010 |
Why?
|
Warts | 1 | 1990 | 19 | 0.010 |
Why?
|
Hand Dermatoses | 1 | 1990 | 25 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2008 | 5767 | 0.010 |
Why?
|
Macrophage Colony-Stimulating Factor | 1 | 1990 | 72 | 0.010 |
Why?
|
Arginine | 1 | 1993 | 500 | 0.010 |
Why?
|
Acute-Phase Proteins | 1 | 1989 | 79 | 0.010 |
Why?
|
Skin Tests | 1 | 1989 | 96 | 0.010 |
Why?
|
Nitric Oxide | 1 | 1993 | 644 | 0.010 |
Why?
|
Hematopoiesis | 1 | 1992 | 560 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1990 | 931 | 0.010 |
Why?
|
Immunologic Memory | 1 | 1989 | 374 | 0.000 |
Why?
|
Pronase | 1 | 1985 | 5 | 0.000 |
Why?
|
Pilot Projects | 1 | 1993 | 2803 | 0.000 |
Why?
|
Pulmonary Alveoli | 1 | 1985 | 208 | 0.000 |
Why?
|
Astrocytoma | 1 | 1987 | 321 | 0.000 |
Why?
|
Amino Acid Sequence | 1 | 1990 | 4233 | 0.000 |
Why?
|
Molecular Sequence Data | 1 | 1990 | 6089 | 0.000 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1983 | 220 | 0.000 |
Why?
|
Bone Marrow | 1 | 1990 | 2358 | 0.000 |
Why?
|
B-Lymphocytes | 1 | 1987 | 1294 | 0.000 |
Why?
|